Format

Send to

Choose Destination
BMC Public Health. 2016 Oct 21;16(1):1103.

Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.

Author information

1
GSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium. Katsiaryna.x.holl@gsk.com.
2
GSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium.
3
University of Palermo, Via Del Vespro 133, 90127, Palermo, Italy.
4
Present Address: Unit of Epidemiology, ATS Brianza, Viale Elvezia 2, 20900, Monza, Italy.
5
University of Florence, Viale GB Morgagni, 48, 50134, Florence, Italy.
6
University of Ferrara, Via Fossato di Mortara 64b, 44121, Ferrara, Italy.

Abstract

BACKGROUND:

Varicella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget.

METHODS:

Scenarios assessed the impact of different vaccination strategies on reduction of varicella disease in the population. A dynamic transmission model was used and adapted to fit Italian demographics and population mixing patterns. Inputs included coverage, number of doses, dosing intervals, first-dose efficacy and availability of catch-up programmes, based on strategies currently used or likely to be used in different countries. The time horizon was 30 years.

RESULTS:

Both one- and two-dose routine varicella vaccination strategies prevented a comparable number of varicella cases with complications, but two-doses provided broader protection due to prevention of a higher number of milder varicella cases. A catch-up programme in susceptible adolescents aged 10-14 years old reduced varicella cases by 27-43 % in older children, which are often more severe than in younger children. Coverage, for all strategies, sustained at high levels achieved the largest reduction in varicella. In general, a 20 % increase in coverage resulted in a further 27-31 % reduction in varicella cases. When high coverage is reached, the impact of dosing interval and first-dose vaccine efficacy had a relatively lower impact on disease prevention in the population. Compared to the long (11 years) dosing interval, the short (5 months) and medium (5 years) interval schedules reduced varicella cases by a further 5-13 % and 2-5 %, respectively. Similarly, a 10 % increase in first-dose efficacy (from 65 to 75 % efficacy) prevented 2-5 % more varicella cases, suggesting it is the least influential factor when considering routine varicella vaccination.

CONCLUSIONS:

Vaccination strategies can be implemented differently in each country depending on their needs, infrastructure and healthcare budget. However, ensuring high coverage remains the critical success factor for significant prevention of varicella when introducing varicella vaccination in the national immunisation programme.

KEYWORDS:

Coverage; Dosing interval; Efficacy; Routine varicella vaccination impact; Varicella

PMID:
27769206
PMCID:
PMC5073465
DOI:
10.1186/s12889-016-3738-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center